Share
Transforming Growth Factor-Beta in Cancer Therapy, Volume II: Cancer Treatment and Therapy
Jakowlew, Sonia B. ; Heldin, C. -H (Author)
·
Humana
· Hardcover
Transforming Growth Factor-Beta in Cancer Therapy, Volume II: Cancer Treatment and Therapy - Jakowlew, Sonia B. ; Heldin, C. -H
£ 231.42
£ 257.13
You save: £ 25.71
Choose the list to add your product or create one New List
✓ Product added successfully to the Wishlist.
Go to My WishlistsIt will be shipped from our warehouse between
Monday, July 15 and
Tuesday, July 16.
You will receive it anywhere in United Kingdom between 1 and 3 business days after shipment.
Synopsis "Transforming Growth Factor-Beta in Cancer Therapy, Volume II: Cancer Treatment and Therapy"
Transforming Growth Factor-B in Cancer Therapy, Volume II: Cancer Treatment and Therapy The chapters in this volume confer an abundance of knowledge about the current state ofour understanding oftransforming growth factor-B (TGF-B) in cancer treatment and therapy. Unlike several more traditional positive polypeptide growth factors that stim- ulate cellular proliferation, the prototypical TGF-B is now known to inhibit the growth of most normal cell types, including those of epithelial and mesenchymal origin. However, there are examplesofcell types that can be stimulated by TGF-B under certain conditions. TGF-B also induces the accumulation of matrix molecules by stimulating their synthesis as well as inhibiting their degradation. Moreover, TGF-B induces apoptosis of certain cell types, thereby restricting their proliferation. OveractivityofTGF- has been linked to several diseases. For instance, the effect ofTGF- on matrix accumulation contributes to fibrotic conditions, like glomerulonephritis, lung fibrosis and liver cirrhosis (1). TGF- has a very complicated role in cancer that is only beginning to be understood.